XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2024
Feb. 19, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol APLS    
Entity Registrant Name APELLIS PHARMACEUTICALS, INC.    
Entity Central Index Key 0001492422    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   125,515,813  
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Public Float     $ 4.2
Entity Current Reporting Status Yes    
Entity File Number 001-38276    
Entity Tax Identification Number 27-1537290    
Entity Address, Address Line One 100 Fifth Avenue    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 617    
Local Phone Number 977-5700    
Entity Interactive Data Current Yes    
Security 12b Title Common Stock, $0.0001 par value per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
Document Financial Statement Error Correction false    
ICFR Auditor Attestation Flag true    
Auditor Name Deloitte & Touche LLP    
Auditor Firm ID 34    
Auditor Location Boston, Massachusetts    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Apellis Pharmaceuticals, Inc. and subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2025, expressed an unqualified opinion on the Company’s internal control over financial reporting.

    
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A in connection with its 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2024. Portions of such proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.